Current Issue: April 2024
Feature Article
The Role of Noncovalent BTK Inhibitors in the Era of Covalent BTK Inhibitors
Abstract: Despite significantly improving outcomes in patients with B-cell malignancies, covalent Bruton tyrosine kinase (BTK) inhibitors are limited by toxicities and the development of resistance. Some […]
Feature Article
Immunotherapy in the Treatment of Advanced or Recurrent Endometrial Cancer
Abstract: The standard treatment of patients with advanced or recurrent endometrial cancer has not significantly changed over the past few decades, reflecting a major unmet clinical […]
Letter From the Editor
Letter From the Editor: Empty Nest
Spring is here, which means graduation time, among other things. My youngest daughter is about to graduate from college and will be home briefly for the […]
Highlights
Highlights in Prostate Cancer From the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium
January 25-27, 2024 • San Francisco, California and Virtual Abiraterone Plus Olaparib Improves Outcomes in Metastatic Castration-Resistant Prostate Cancer A combination of abiraterone and olaparib (Lynparza, […]
Advances in Hematology
Thrombotic Complications of Influenza and COVID-19 Infections
H&O How often do influenza and COVID-19 lead to thrombotic complications? PN The true incidence of thrombotic complications with influenza and COVID-19 is unclear. A study […]
Advances in Drug Development
Coordination Between the FDA and the US Patent and Trademark Office
H&O What is the Executive Order on Promoting Competition in the American Economy and how does it relate to coordination between the FDA and the USPTO? […]
CLL
Six-Year Update of the ELEVATE-TN Study on Acalabrutinib
H&O Could you describe the impetus for and design of the ELEVATE-TN trial? JS The ELEVATE-TN study was conducted to seek regulatory authorization for acalabrutinib (Calquence, […]